Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Autoantibody to High Prevalence Kel System Antigen

Thane Kubik, Craig Tausher, Jenny Schieber, Alana Sutherland, Karen Lund, Justin Juskewitch, Maggie DiGuardo, Jeffrey Winters

Blood (2024) 144 (Supplement 1): 5219.

https://doi.org/10.1182/blood-2024-199785

Published: 2024

Journal Articles

Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000.

Charles Bennett, MD, PhD, MPP, Masanori Matsumoto, MD, Peter Georgantopoulos, MPH, AM, Sony Jacob, MD, Brianne L Dunn, PharmD, Zaina Parvez Qureshi, PhD, MPH, Nicholas Bandarenko, III, MD, Hau C. Kwaan, MD, PhD, Jeffrey Winters, MD, Ravindra Sarode, MD, Joseph E Kiss, MD, Constance Danielson, MD, PhD, Thomas L. Ortel, MD, PhD, Thomas Raife, MD, William F Clark, MD, Gail Rock, PhD, MD, FRCP, X. Long Zheng, MD, PhD, Dennis Raisch, Ph.D., M.S., R.Ph., Yoshihiro Fujimura, MD, PhD

Blood (2012) 120 (21): 2203.

https://doi.org/10.1182/blood.V120.21.2203.2203

Published: 2012

Journal Articles

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy

Shaji Kumar, MD, Joseph R. Mikhael, MD, Martha Q Lacy, MD, Betsy R. LaPlant, Francis K Buadi, M.D., David Dingli, M.D., Ph.D., Morie A Gertz, MD, Teresa Miceli, RN, Marcia Mahlman, P.Leif Bergsagel, MD, Suzanne R Hayman, MD, Craig B. Reeder, MD, Angela Dispenzieri, MD, Dennis A. Gastineau, MD, Jeffrey Winters, MD

Blood (2011) 118 (21): 2992.

https://doi.org/10.1182/blood.V118.21.2992.2992

Published: 2011

Journal Articles

Comparable Outcomes with or without Routine Granulocyte Growth Factor Support Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): A Single Center Experience.

Harris V. Naina, MD, Shaji Kumar, Shekhar Bitla, Jeffrey Winters, MD, William Hogan, MD, Carl Greiner, Dennis Gastineau

Blood (2009) 114 (22): 1178.

https://doi.org/10.1182/blood.V114.22.1178.1178

Published: 2009

Journal Articles

Predicting Poor Peripheral Blood Stem Cell Mobilization Using Initial Peripheral CD34 Counts in Patients with Lymphoma.

Shirshendu Sinha, MBBS, Shaji Kumar, MD, Dennis A. Gastineau, MD, William Hogan, MD, Francis Buadi, MD, David Dingli, PhD., M.D., Angela Dispenzieri, MD, Morie A Gertz, MD, Carl Greiner, Suzzane Hayman, MD, David Inwards, MD, Patrick B Johnston, MD, PhD, Martha Q. Lacy, MD, Mark R. Litzow, MD, Luis F. Porrata, MD, Jeffrey Winters, MD, Ivana N Micallef, MD

Blood (2009) 114 (22): 4228.

https://doi.org/10.1182/blood.V114.22.4228.4228

Published: 2009

Journal Articles

Predicting Poor Peripheral Blood Stem Cell Mobilization in Multiple Myeloma (MM) Using Initial Peripheral CD34 Counts: Developing Target-Based Cut-Points for Early Intervention.

Shirshendu Sinha, MBBS, Dennis A. Gastineau, MD, William J. Hogan, MBBCh, Ivana N Micallef, MD, Francis K. Buadi, MD, David Dingli, M.D., PhD., Angela Dispenzieri, MD, Morie A. Gertz, MD, Carl Greiner, Suzzane Hayman, MD, David J. Inwards, MD, Patrick B. Johnston, MD.Ph.D, Martha Q. Lacy, MD, Mark R. Litzow, MD, Luis F. Porrata, MD, Jeffrey Winters, MD, Shaji Kumar, MD

Blood (2009) 114 (22): 3231.

https://doi.org/10.1182/blood.V114.22.3231.3231

Published: 2009

Journal Articles

Preliminary Results from the Surveillance, Epidemiology & Risk Factors for TTP (SERF-TTP) Group: A Prospective Case-Control Study of Idiopathic TTP.

Anaadriana Zakarija, MD, H.C. Kwaan, MD PhD, Nicholas Bandarenko, MD, Dilip Pandey, MD PhD, Amul Tevar, MS, John Cursio, MS, Charles Buffie, BA, Thomas Ortel, MD PhD, Jeffrey Winters, MD, Joseph Kiss, MD, Ravindra Sarode, MD, Charles Bennett, MD PhD

Blood (2006) 108 (11): 1063.

https://doi.org/10.1182/blood.V108.11.1063.1063

Published: 2006

NARROW

Autoantibody to High Prevalence Kel System Antigen

Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000.

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy

Comparable Outcomes with or without Routine Granulocyte Growth Factor Support Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): A Single Center Experience.

Predicting Poor Peripheral Blood Stem Cell Mobilization Using Initial Peripheral CD34 Counts in Patients with Lymphoma.

Predicting Poor Peripheral Blood Stem Cell Mobilization in Multiple Myeloma (MM) Using Initial Peripheral CD34 Counts: Developing Target-Based Cut-Points for Early Intervention.

Preliminary Results from the Surveillance, Epidemiology & Risk Factors for TTP (SERF-TTP) Group: A Prospective Case-Control Study of Idiopathic TTP.

Email alerts

ASH Publications

American Society of Hematology

Autoantibody to High Prevalence Kel System Antigen

Deficient ADAMTS13 Activity in Ticlopidine-Associated Thrombotic Thrombocytopenic Purpura (TTP) in Populations From Japan in 2012: Validation of Findings Initially Reported in the United States in 1998 and 2000.

Phase II Trial of Intravenously Administered AMD3100 (Plerixafor) for Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Following a Lenalidomide-Based Initial Therapy

Comparable Outcomes with or without Routine Granulocyte Growth Factor Support Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT): A Single Center Experience.

Predicting Poor Peripheral Blood Stem Cell Mobilization Using Initial Peripheral CD34 Counts in Patients with Lymphoma.

Predicting Poor Peripheral Blood Stem Cell Mobilization in Multiple Myeloma (MM) Using Initial Peripheral CD34 Counts: Developing Target-Based Cut-Points for Early Intervention.

Preliminary Results from the Surveillance, Epidemiology & Risk Factors for TTP (SERF-TTP) Group: A Prospective Case-Control Study of Idiopathic TTP.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only